Back to top
more

Revolution Medicines (RVMD)

(Delayed Data from NSDQ)

$37.11 USD

37.11
1,247,740

+1.15 (3.20%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $37.12 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RVMD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Revolution Medicines, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,853 645 577 441 123
Receivables 1 5 6 6 9
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 25 11 7 7 2
Total Current Assets 1,879 660 590 454 134
Net Property & Equipment 23 19 12 9 7
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 72 73 74 76 77
Deposits & Other Assets 10 5 3 1 3
Total Assets 2,062 812 738 567 221
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 62 21 14 13 11
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 75 29 28 19 15
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 4 12 12 17
Total Current Liabilities 144 62 60 47 43
Mortgages 0 0 0 0 0
Deferred Taxes/Income 3 7 14 16 24
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 8 0 1 1 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 236 127 135 93 68
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 305
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,963 1,388 1,056 740 5
Retained Earnings -1,138 -701 -453 -266 -157
Other Equity 1 -2 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,826 685 603 475 153
Total Liabilities & Shareholder's Equity 2,062 812 738 567 221
Total Common Equity 1,826 685 603 475 -153
Shares Outstanding 164.60 88.70 73.60 66.30 NA
Book Value Per Share 11.09 7.72 8.19 7.16 0.00

Fiscal Year End for Revolution Medicines, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 1,853 813 909 910
Receivables NA 1 0 3 4
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 25 11 10 9
Total Current Assets NA 1,879 824 922 923
Net Property & Equipment NA 23 20 20 19
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 72 73 73 73
Deposits & Other Assets NA 10 14 5 5
Total Assets NA 2,062 984 1,074 1,073
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 62 30 30 20
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 75 50 43 27
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 1
Total Current Liabilities NA 144 86 78 55
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 3 3 7 7
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1 0 2
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 236 147 143 121
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,963 1,814 1,800 1,722
Retained Earnings NA -1,138 -976 -868 -769
Other Equity NA 1 -1 -1 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,826 837 931 952
Total Liabilities & Shareholder's Equity NA 2,062 984 1,074 1,073
Total Common Equity 0 1,826 837 931 952
Shares Outstanding 164.60 164.60 109.40 106.30 106.30
Book Value Per Share 0.00 11.09 7.66 8.76 8.96